OR WAIT 15 SECS
June 23, 2016
Of the three major indications within hematological cancer -- leukemia, lymphoma and myeloma -- leukemia has the largest pipeline, with 798 products in active development, while lymphoma has 552 and myeloma has 396, according to GBI Research.
The company’s latest report states that there are currently 1,234 pipeline products in active development in the hematological cancer therapy area, and for each of the three key indications, the composition by stage of development is relatively similar, although leukemia and myeloma have more products in clinical development.
The report also states that considerable unmet needs remain in hematological cancer, with acute myeloid leukemia (AML) particularly ill-served, as there is a need for more efficacious targeted therapies across all patient subtypes. The treatment of AML is still limited to conventional DNA-targeted chemotherapy regimens, which achieve long-term survival rates of 25-50% in patients below the age of 60, and only 5-15% in older patients, indicating a clear need for more efficacious treatments.